MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis

References

• Eslam M , Sanyal AJ , George J . MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology . 2020;158(7):1999–2014.e1991. doi:10.1053/j.gastro.2019.11.312 32044314
   PubMed Web of Science ®Google Scholar
• Valenti L , Pelusi S . Redefining fatty liver disease classification in 2020. Liver Int . 2020;40(5):1016–1017. doi:10.1111/liv.14430 32352234
   PubMed Web of Science ®Google Scholar
• EASL E. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol . 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004 27062661
   PubMed Web of Science ®Google Scholar
• Fouad Y , Waked I , Bollipo S , et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int . 2020;40(6):1254–1261. doi:10.1111/liv.14478 32301554
   PubMed Web of Science ®Google Scholar
• Eslam M , Newsome PN , Sarin SK , et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol . 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039 32278004
   PubMed Web of Science ®Google Scholar
• Wai-Sun Wong V , Lai-Hung Wong G , Woo J , et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol . 2020. doi:10.1016/j.cgh.2020.10.046
   Web of Science ®Google Scholar
• Zheng KI , Sun DQ , Jin Y , et al. Clinical utility of the MAFLD definition. J Hepatol . 2021;74(4):989–991. doi:10.1016/j.jhep.2020.12.016 33347953
   PubMed Web of Science ®Google Scholar
• Sun DQ , Jin Y , Wang TY , et al. MAFLD and risk of CKD. Metabolism . 2021;115:154433. doi:10.1016/j.metabol.2020.154433 33212070
   PubMed Web of Science ®Google Scholar
• Majumdar A , Tsochatzis E . Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism . 2020;111:154291. doi:10.1016/j.metabol.2020.154291
   Web of Science ®Google Scholar
• Cotter T , Dong L , Holmen J , et al. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. J Gastroenterol . 2020;55(7):722–730. doi:10.1007/s00535-020-01684-w 32328797
   PubMed Web of Science ®Google Scholar
• Lin S , Huang J , Wang M , et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int . 2020;40(9):2082–2089. doi:10.1111/liv.14548 32478487
   PubMed Web of Science ®Google Scholar
• Huang J , Kumar R , Wang M , et al. MAFLD criteria overlooks a number of patients with severe steatosis: is it clinically relevant? J Hepatol . 2020;73(5):1265–1267. doi:10.1016/j.jhep.2020.06.016 32819754
   PubMed Web of Science ®Google Scholar
• Wu Y , Kumar R , Huang J , et al. FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD). J Hepatol . 2021;74(1):247–248. doi:10.1016/j.jhep.2020.06.040 32994079
   PubMed Web of Science ®Google Scholar
• Wang FS , Fan JG , Zhang Z , et al. The global burden of liver disease: the major impact of China. Hepatology . 2014;60(6):2099–2108. doi:10.1002/hep.27406 25164003
   PubMed Web of Science ®Google Scholar
• Bell S , Lau A , Thompson A , et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J Clin Virol . 2005;32(2):122–127. doi:10.1016/j.jcv.2004.10.009 15653414
   PubMed Web of Science ®Google Scholar
• Kleiner DE , Brunt EM , Van Natta M , et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology . 2005;41(6):1313–1321. doi:10.1002/hep.20701 15915461
   PubMed Web of Science ®Google Scholar
• Brunt EM . Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology . 2000;31(1):241–246. doi:10.1002/hep.510310136 10613753
   PubMed Web of Science ®Google Scholar
• Scheuer PJ . Classification of chronic viral hepatitis: a need for reassessment. J Hepatol . 1991;13(3):372–374. doi:10.1016/0168-8278(91)90084-O 1808228
   PubMed Web of Science ®Google Scholar
• Hong M , Zhang R , Chen G , et al. Liver stiffness measurement-based scoring system for significant inflammation related to chronic hepatitis B. PLoS One . 2014;9(10):e111641. doi:10.1371/journal.pone.0111641 25360742
   PubMed Web of Science ®Google Scholar
• Lu FB , Zheng KI , Rios RS , et al. Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol . 2020;35(12):2041–2050. doi:10.1111/jgh.15156 32573017
   PubMed Web of Science ®Google Scholar
• Eslam M , Fan JG , Mendez-Sanchez N . Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. Lancet Gastroenterol Hepatol . 2020;5(8):713–715. doi:10.1016/S2468-1253(20)30090-X 32413341
   PubMed Web of Science ®Google Scholar
• Ye Q , Zou B , Yeo YH , et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol . 2020;5(8):739–752. doi:10.1016/S2468-1253(20)30077-7 32413340
   PubMed Web of Science ®Google Scholar
• Hagström H , Nasr P , Ekstedt M , et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun . 2018;2(1):48–57. doi:10.1002/hep4.1124 29404512
   PubMed Web of Science ®Google Scholar
• Francque S , Laleman W , Verbeke L , et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest . 2012;92(10):1428–1439. doi:10.1038/labinvest.2012.103 22890552
   PubMed Web of Science ®Google Scholar
• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet . 2004;363(9403):157–163. doi:10.1016/S0140-6736(03)15268-3 14726171
   PubMed Web of Science ®Google Scholar
• Huang J , Jing M , Wang C , et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: a population-based study. J Med Virol . 2020;92(8):1191–1197. doi:10.1002/jmv.25621 31691993
   PubMed Web of Science ®Google Scholar
• Huang J , Ou W , Wang M , et al. MAFLD criteria guide the subtyping of patients with fatty liver disease. Risk Manag Healthc Policy . 2021;14:491–501. doi:10.2147/RMHP.S285880 33603515
   PubMed Web of Science ®Google Scholar
• Yamamura S , Eslam M , Kawaguchi T , et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int . 2020;40(12):3018–3030. doi:10.1111/liv.14675 32997882
   PubMed Web of Science ®Google Scholar
• Wang MF , Wan B , Wu YL , et al. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection. World J Gastroenterol . 2021;27(4):336–344. doi:10.3748/wjg.v27.i4.336 33584066
   PubMed Web of Science ®Google Scholar